About the author



  • I cannot see a good reason why the drug shouldn't work in SP if it does in PPMS given we generally find more inflammatory lesions/blood-brain-barrier disruption in SP, something Ocrelizumab gets rid of quite effectively. Whether regulators agree, whether the company will even apply for a respective license is a different matter. Disease course definition is also changing, and there was a session dedicated to this here in Barcelona today, so it'll be interesting to see how the new classification aligns with data gathered using the older guidance.

    • Maybe if it is used on SPMS there will be a quicker result of it's efficacy. It can't be proven so early in PPMS or RRMS, so it wouldn't be worth applying for a license for SPMS. Look forward to hearing about the new classification.

    • I wouldn't know where to get Ocrelizumab. You might have a chance somebody would prescribe Rituximab, but very much depends on circumstances. Disclosure: I don't advise on individual treatment online.

  • Is this as big a breakthrough as were led to believe or is this a case of the media sensationalising in order to sell news?

    If it is, to what rate do we think this will slow progression?
    I.e. Average time to edss 6 is for example 8 years, where should we expect this to be?

    And apologies for the additional questions, but would this not increase life expectancy of people with progressive ms by slowing time to relevant edss levels

    Once again kudos to all Involved, and I personally would not begrudge anyone involved getting very wealthy from it, the price that added time with loved ones and a better qol is worth it

By MouseDoctor



Recent Posts

Recent Comments